![]() |
市場調查報告書
商品編碼
1496072
北美的動物用藥市場 - 全球產業分析,規模,佔有率,成長,趨勢,預測(2031年)- 各產品,各動物類型,各終端用戶,各國North America Vet Compounding Pharmacies Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America) |
北美動物用藥市場近年來經歷了穩定成長。這種擴張主要是由於寵物主人對動物健康的認識不斷提高,以及對藥物在治療各動物種疾病方面發揮的重要作用的認識。預計該市場將持續呈上升趨勢,2024年達到14.8億美元,2031年達到27億美元。
推動市場成長的主要因素是寵物主人對寵物健康的意識不斷增強。根據美國寵物產品協會和美國獸醫協會 (AVMA) 的報告,美國約有 8,490 萬個家庭養寵物。越來越多的寵物主人增加了對獸醫護理和針對其特定需求的複合藥物的需求。
仿製藥動物用藥的高價格和容易取得也是促進市場擴張的因素。獲得許可的藥局為那些更喜歡這些藥物而不是更昂貴的品牌藥物的寵物主人提供了更實惠和更方便的選擇。這種趨勢在寵物照護費用過高的低收入家庭中尤其明顯。
本報告提供北美的動物用藥市場相關調查,提供市場概要,以及各產品,各動物類型,各終端用戶,各國趨勢,及市場參與市場企業的競爭趨勢等資訊。
The North American veterinary compounding pharmacies market has experienced robust growth in recent years. This expansion is largely driven by the increasing awareness among pet owners about animal health and the critical role of compounded medications in treating various conditions in animals. The market is expected to continue its upward trajectory, with a projected size of US$ 1.48 billion in 2024 and US$ 2.7 billion by 2031.
Key Drivers of Market Growth
Increasing Awareness and Pet Ownership
A primary factor propelling market growth is the heightened awareness of pet health among owners. Reports from the American Pet Product Association and the American Veterinary Medical Association (AVMA) indicate that nearly 84.9 million households in the U.S. own pets. This rise in pet ownership has led to a greater demand for veterinary care and compounded medications tailored to specific needs.
Cost and Availability of Generic Veterinary Drugs
The high cost and limited availability of generic veterinary drugs have also contributed to market expansion. Authorized compounding pharmacies provide more affordable and accessible options for pet owners, who often find these medications preferable to expensive branded drugs. This trend is especially notable in low-income households where the cost of animal care can be prohibitive.
Market Segmentation
CNS Agents Leading the Market
The CNS agents segment is anticipated to hold the largest market value, reaching approximately US$ 517.6 million in 2023. CNS medications are crucial for treating conditions such as attention deficit hyperactivity disorder (ADHD) in companion animals, particularly dogs, significantly contributing to market growth.
Companion Animals Dominate the Market
The companion animal segment, driven by the growing humanization of pets and increasing adoption rates, is expected to dominate the market. This segment is projected to hold around 58.7% of the market share.
Oral Formulations Preferred
Oral formulations are the most preferred method of drug administration in the veterinary sector due to their non-invasive nature, ease of administration, and patient compliance. This segment is expected to capture approximately 75.3% of the market share.
Regional Insights
U.S. Market Holds Significant Share
The U.S. is projected to maintain its dominance in the North American vet compounding pharmacies market, holding around 87.9% of the regional market share. The country's robust regulatory environment, expanding pharmaceutical sector, and increasing demand for diverse animal medications are key factors contributing to its leading position.
Canada's Growing Market Share
Canada is expected to hold a market share of around 12.1%. The increasing popularity of pet ownership and heightened awareness of animal healthcare are driving market growth in the country. Additionally, the introduction of new products by major players is bolstering the market.
Competitive Analysis
Leading companies in the North American vet compounding pharmacies market are focusing on expanding their customer base and enhancing their market presence through the development and launch of new and improved medications. The top four companies account for approximately 35.8% of the market share.
Key Developments
In January 2021, the FDA issued a recommendation titled GFI #256, outlining the conditions under which it would not enforce laws against the bulk manufacturing of medications. This recommendation supports the development of necessary antidotes for poisons found in animal food and significant differences between compounded medications and FDA-approved drugs with the same active ingredients.
In October 2020, Virbac introduced STELFONTA, a novel injectable treatment for canine mast cell tumors, the most common form of skin cancer in dogs. This treatment demonstrated a high rate of tumor eradication and marked a significant advancement in veterinary oncology.
Hoye's Pharmacy
Vertisis Custom Pharmacy
Smith Caldwell Drug Store
Sixth Avenue Medical Pharmacy
Dougherty Pharmacy
Triangle Compounding Pharmacy Inc.
Wedgewood Pharmacy
Millers Pharmacy
Chiron Compounding Pharmacy
MEDS Canadian Compounding Pharmacy
Aurora Compounding
Pace Pharmacy
Victoria Compounding Pharmacy
Pratt's Compounding Pharmacy
People's Choice Pharmacy
CNS Agents
Anti-Infective Agents
Hormones and Substitutes
Anti-inflammatory Agents
Others
Companion Animals
Dogs
Cats
Equine
Others
Livestock Animals
Oral
Injectable
Others
U.S.
Canada